Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report) yesterday and set a price target of $35.00. The company's shares opened today at $12.63.McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Adial Pharmaceuticals, and Lineage Cell Therapeutics. According to TipRanks, McCarthy has an average return of -40.3% and a 12.87% success rate on recommended stocks. Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $30.00, a 137.53% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $24.00 price target.
https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-actinium-pharmaceuticals-atnm?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Jan 2023 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Fév 2022 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals